1. Home
  2. CRNX vs FICO Comparison

CRNX vs FICO Comparison

Compare CRNX & FICO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$36.78

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Fair Isaac Corproation

FICO

Fair Isaac Corproation

HOLD

Current Price

$1,093.95

Market Cap

34.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
FICO
Founded
2008
1956
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
34.7B
IPO Year
2018
1995

Fundamental Metrics

Financial Performance
Metric
CRNX
FICO
Price
$36.78
$1,093.95
Analyst Decision
Strong Buy
Buy
Analyst Count
8
13
Target Price
$76.75
$1,689.92
AVG Volume (30 Days)
1.3M
362.9K
Earning Date
05-07-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.78
EPS
N/A
17.73
Revenue
$1,039,000.00
$1,032,475,000.00
Revenue This Year
$720.10
$27.28
Revenue Next Year
$184.67
$16.97
P/E Ratio
N/A
$61.26
Revenue Growth
N/A
N/A
52 Week Low
$25.83
$870.01
52 Week High
$57.99
$2,217.60

Technical Indicators

Market Signals
Indicator
CRNX
FICO
Relative Strength Index (RSI) 42.84 53.68
Support Level $33.19 $1,068.67
Resistance Level $37.23 $1,117.39
Average True Range (ATR) 2.32 46.68
MACD -0.33 9.20
Stochastic Oscillator 13.52 76.85

Price Performance

Historical Comparison
CRNX
FICO

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About FICO Fair Isaac Corproation

Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.

Share on Social Networks: